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ABSTRACT
Wourms, Michael J. M.S., Department of Pharmacology and Toxicology, Wright
State University, 2013. The aryl hydrocarbon receptor regulates an essential
transcriptional element in the immunoglobulin heavy chain gene.

2,3,7,8-tetrachlorodibenzo-ρ-dioxin (TCDD) is a ubiquitous environmental
contaminant that inhibits immunoglobulin (Ig) expression and Ig heavy (IgH)
chain gene transcription. Transcription of the IgH gene involves several
regulatory elements including the 3'Igh regulatory region (3'IghRR) which is
composed of four enhancers (hs3A, hs1,2, hs4, and hs3B). Dioxin responsive
elements (DRE) in the hs4 and hs1,2 enhancers of the 3’IghRR that bind the aryl
hydrocarbon receptor (AhR), a ligand-activated transcription factor that regulates
dioxin sensitive genes suggest that the 3'IghRR may be a transcriptional target
of TCDD. The current study utilized an IgA secreting mouse B-cell line that
stably expresses a γ2b transgene regulated by the 3'IghRR (CH12.γ2b-3'IghRR
cells). Both shRNA knock down of AhR and an AhR antagonist (CH-223191)
reduced TCDD-induced inhibition of endogenous IgA and the γ2b transgene
expression. With the growing number of immune-related disorders correlated
with polymorphisms of the human hs1,2 enhancer, ubiquitously found AhR
ligands, and sensitivity of human Ig expression to TCDD, our findings may
provide indispensible information for human health risk assessment and insight
into the development of therapeutic interventions for immune-related disease.
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I.

INTRODUCTION

The aryl hydrocarbon receptor (AhR) is a ligand-activated basic-helix-loophelix (bHLH) transcription factor most well known for mediating the toxic effects
of 2,3,7,8-tetrachlorodibenzo-ρ-dioxin or TCDD (Fig. 1) as well as other dioxin
congeners. In its quiescent state, the AhR resides in the cytoplasm sequestered
by chaperone proteins p23, XAP2, and two heat shock 90 proteins. Once bound
by ligand, AhR translocates to the nucleus heterodimerizing with the aryl
hydrocarbon nuclear translocator (ARNT) protein forming a functional
transcription factor that binds to cis-acting sequences known as dioxin
responsive elements (DREs) in the regulatory regions of AhR-sensitive genes
(Fig. 2) (Reviewed by Abel and Haarmann-Stemmann, 2010 and Ma et al.,
2009). Although TCDD and other dioxin congeners are the prototypical
compounds by which the AhR has been studied, a variety of nondioxin agonist
have recently been discovered including those of pharmaceutical and dietary
origins (Quattrochi and Tukey, 1993; Werlinder at al., 2000; Jeuken et al., 2003).
Canonically, AhR is known to modulate the xenobiotic enzyme battery
specifically cytochrome P4501A1 (Cyp1A1) but recent evidence supports AhR
regulation of genes important to adaptive immunity including the inflammatory
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cytokine Interluekin 6 and immunoglobulin (Ig) (DiNatale et al., 2010, DiNatale et
al., 2011, Sulentic and Kaminski, 2010). Indeed, we have recently shown variety
of dioxin and non dioxin AhR agonists inhibit Ig expression in the CH12.LX
murine B cell line however the BCL-1 cell line which does not express the AhR is
insensitive to treatment with TCDD and other dioxin congeners (Henseler et al.,
2009; Sulentic et al., 1997). Similarly, Vorderstrasse et al. (2001) demonstrated
that AhR-/- mice generate a normal Ig response to antigens despite TCDD
treatment.

Figure 1. Chemical structure of 2,3,7,8-tetrachlorodibenzo-ρ-dioxin (TCDD).
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Figure 2. The aryl hydrocarbon receptor (AhR) signaling pathway.
sequestered in the cytosol by chaperone proteins p23, XAP2, and hsp90, upon
ligand-binding the AhR-complex translocates to the nucleus where it sheds the
chaperone proteins, heterodimerizing with the aryl hydrocarbon receptor nuclear
translocator protein (AhRNT). The AhR-AhRNT complex binds dioxin responsive
elements (DRE) in the regulatory regions of dioxin-sensitive genes interacting
with the basal transcription apparatus and other transcription factors causing
changes in transcription (e.g. increasing the transcription of Cyp1A1).
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Clearly, the AhR plays an obligatory role during TCDD dependent
inhibition of Ig expression in B cells however a mechanism has yet to be
characterized and an Ig regulatory target for the AhR not identified. Responsible
for humoral immunity, the Ig is a tetrameric protein comprised of two identical
heavy (IgH) and light (IgL) chain peptides (Fig. 3). The genes encoding IgH and
IgL (Igh and Igl) require coordinated expression for effective assembly and
expression. Interestingly TCDD not only inhibits Ig protein expression in
CH12.LX cells but also transcription of Igh and Igl (Fernando et al., 2012;
Henseler et al., 2009; Yoo et al., 2004; Sulentic et al., 2000).
Of the Ig genes, regulation of Igh is the best understood and is achieved
through a variable heavy chain promoter (VH), an intronic enhancer (Eµ), and the
3’Igh regulatory region (3'IghRR)(Fig. 4). Primarily activated in terminally
differentiated plasma B cells, the 3’IghRR provides for high Igh expression in
plasma B cells as well as class-switch recombination (CSR), a DNA
recombination event during which the type of Ig expressed is changed from IgM
to one (e.g. IgG, IgE, or IgA) that interacts with a separate array of effector
molecules and cells (Pinaud et al., 2001; Cogne et al., 1994, Dunnick et al.,
2005). The murine 3’IghRR (mo-3’IghRR) contains four DNase I hypersensitivity
sites (hs3A, hs1,2, hs4, and hs3B) that act as enhancers (Reviewed by
Khamlichi et al., 2000). Our lab has previously characterized two DREs capable
of binding ligand-activated AhR in the hs1,2 and hs4 enhancers suggesting this
region is sensitive to TCDD-AhR (Sulentic et al., 2000). Indeed both transiently
and stably expressed 3'IghRR reporter constructs are down regulated by TCDD
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in CH12.LX cells (Henseler et al., 2009). Furthermore, studies reveal that
3’IghRR activity is inhibited with greater potency by ligand with higher affinity for
the AhR protein (Henseler at al., 2009).
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Figure 3. Structure of an immunoglobulin (Ig) protein. In its secreted form Ig
is composed of two identical heavy chain and light chain proteins each with a
constant region that determines the effector qualities of the Ig and a variable
region that binds antigens.
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Figure 4. Schematic of the mouse immunoglobulin heavy chain gene
locus. VH, variable heavy chain promoter; Eµ, intronic enhancer (µ) enhancer;
closed black rectangles, germline promoters upstream of their heavy chain
constant region; 3ˊ IghRR, 3ˊ immunoglobulin heavy chain regulatory region
containing the hs3a, hs1,2, hs3b, and hs4 enhancers.
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Although previous studies suggest AhR regulates Ig expression through
modulating the 3'IghRR, the data is correlative and a conclusive link has yet to be
drawn. In the current study we utilized an IgA expressing CH12.LX variant that
stably expresses the previously characterized 3'IghRR-regulated γ2b-transgene
(Henseler et al., 2009). We show that by both pharmacologically inhibiting the
AhR and stably knocking down AhR expression in this cellular model, TCDDinduced inhibition of IgA expression and 3'IghRR can be fully reversed. We
address a critical mechanistic data gap showing that the AhR is responsible for
TCDD-induced inhibition of Ig by inhibiting the capacity of the 3'IghRR to
increase expression of Ig. We also identify the AhR as a previously unknown
regulator of the 3'IghRR. The 3'IghRR is a critical component of B-cell function
as maintaining high levels of Ig expression in plasma cells and regulating class
switch recombination are paramount to mounting an effective immune response.
Any dysregulation of these processes has significant health ramifications. In
addition the 3'IghRR has also been associated with several diseases including
Burkitt’s lymphoma, celiac disease, and IgA nephropathy (Wang et al., 2005;
Frezza et al., 2004; Auptetit et al., 2000). Therefore, modulation of the 3'IghRR
by AhR via environmentally ubiquitous dioxin and nondioxin agonists has the
potential to influence the severity and/or incidence of human disease.
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II.

MATERIALS AND METHODS

Chemicals and Reagents
AhR antagonist (CH-223191) was purchased from EMD4Biosciences at > 95%
purity (Newark, NJ) and suspended in 100% dimethyl sulfoxide (DMSO). TCDD
(99.1% purity) in 100% DMSO was purchased from Accustandard (New Haven,
CT). DMSO and lipopolysaccharide (LPS, Escherichia coli) were purchased from
Sigma-Aldrich (Atlanta, GA).
Cell Model
The CH12.γ2b-3'IghRR cell line, developed by our lab (Henseler et al., 2009), is
a variant of the CH12.LX murine B cell line derived from the CH12 murine B cell
lymphoma arising in B10.H-2aH-4bp/Wts mice (Arnold at al., 1983). The
CH12.γ2b-3’IghRR cell line was generated from an IgA expressing CH12.LX
clone and stably expresses a 3'IghRR-regulated γ2b-transgene with loxP sites
flanking the hs3B and hs4 enhancer pair generously provided by Dr. Laurel
Eckhardt from Hunter College, New York, NY (Figure 5; Shi and Eckhardt, 2001).
PCR and ELISA analysis verified that CH12.γ2b-3'IgH cells do not contain an
endogenous form of the γ2b gene. The γ2b-transgene is sensitive to activation
by LPS through TLR4 signaling with maximal transgene expression 48 hours
post LPS treatment (Henseler et al., 2009). All cells were grown in a 37˚C
incubator with 5% CO2 injection. Cells were maintained in RPMI 1640
9

(Mediatech, Herndon, VA) media supplemented with 10% bovine calf serum
(Hyclone Laboratories, Logan, UT), 0.1 mM nonessential amino acids, 1 mM
sodium pyruvate, 13.5 mM HEPES, 100 units/mL penicillin, 50 µM 2mercaptoethanol, and 100 µg/mL streptomycin (Hyclone Laboratories).
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Figure 5. Schematic of the γ2b transgene and endogenous IgA locus in the
CH12.γ2b-3'IghRR cell line. Top; Schematic of the γ2b transgene, composed of
the γ2b reporter protein regulated by the variable heavy chain promoter (VH) and
the 3'IghRR. Bottom; Schematic of the endogenous IgA locus native to the
CH12.γ2b-3'IghRR cell line composed of the VH, variable heavy chain promoter,
Eµ, intronic enhancer (µ) enhancer, the germline promoter (closed small yellow
rectangle) upstream of the α (IgA) heavy chain constant region followed by the
3'IghRR.
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shRNA Constructs
Two pLKO.1 HIV-based lentiviral vector plasmids containing shRNA sequences
complimentary to AhR (shAhR) and puromycin selectable marker gene were
purchased from Open Biosystems (Huntsville, AL). The shAhR sequences and
target nucleotides in the AhR (Genbank Accession No. NM_013464.4) transcript
are as follows; shAhR11, 5’-AATTTGCTCATGTTTCAGCGC-3’, corresponding to
nucleotide positions 1861-1881, shAhR12, 5’-TAATAACATCTTGCGGGAAGG3’, corresponding to nucleotide positions 527-547. Vectors were packaged into
VSV-G pseudotyped fourth generation lentiviral particles by Cincinnati Children's
Viral Vector Core (Cincinnati, OH) and stored at -80˚C until use.
Stable AhR Knockdown
CH12.γ2b-3'IgH cells (5 x 103 cells/mL) were suspended in media containing 16
µg/mL polybrene (American Bioanalytical, Natick, MA) and 0.1 mL (500 cells)
immediately seeded in 96-well culture plates with either shAhR11 or shAhR12containing lentiviral particles. Culture plates were centrifuged for 30 minutes at
1100 x g before supernatants were discarded and replaced with 200 µL media.
After 24 hr the culture plates were centrifuged at 3000 rpm (5 min), the
supernatants replaced with puromycin (Invivogen, San Diego, CA) selective
media (1µg/mL). Puromycin selective media was replaced every 72 hr for
approximately 4 weeks until cell density and culture volumes were sufficient to
harvest whole cell lysate from 10 mL of cells and 1.0 x 106 cell stocks were
frozen in liquid nitrogen for future use.
Chemical Treatment
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Cells were treated with the AhR antagonist, CH-223191, or vehicle (0.1% DMSO)
for one hour prior to treatment with TCDD (10 nM) or the appropriate TCDD
vehicle (0.01% DMSO). For IgA and γ2b analysis, cells were stimulated with
LPS (1 µg/mL), seeded in 24-well culture plates at a concentration of 3.0 x 104
cells/mL and incubated for 48 hours at 37˚C in 5% CO2. For quantitative realtime polymerase chain reaction (qRT-PCR) of Cyp1A1 transcripts; cells were
seeded at 5.0 x 105 cells/mL in 24-well culture plates and incubated for 8 h. No
consistent vehicle effects were seen.
Protein Isolation and Western Blot
Cells were centrifuged at 3000 rpm then lysed with mild lysis buffer (1% NP40,
150 mM NaCl, 2 mM EDTA, 10 mM NaPO4) containing protease inhibitors
(Complete Mini Protease Inhibitor Cocktail; Roche, Indianapolis, IN) and frozen
at -80˚C. Protein quantification was performed by thawing whole cell lysates on
ice prior to centrifugation at 14,000 rpm. Supernatants were collected and
protein content quantified by a Bio-Rad Assay (Hercules, CA). Protein samples
were normalized to 2 µg in 100 µL of 1x PBS in preparation for ELISA analysis.
Naive samples were used for SDS-PAGE and western blotting analysis of AhR
protein expression. 20 µg total protein from NA samples was denatured then run
on 10% polyacrylamide gel at 200 volts for ~40 minutes. Proteins were
transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford,
MA) at 100 volts for 1 h. Membranes were blocked for 1 hour in blocking buffer (
3% bovine serum albumin [BSA], 0.05% tween-20, in tris buffered saline[TBS]),
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incubated with either mouse anti-AhR Ab (Abcam) at a 1:1000 dilution of mouse
anti-β-actin Ab (Sigma Aldrich) at a 1:10,000 dilution in 1% BSA, 0.05% tween-20
in TBS. Membrane was washed four time with TBS with 0.05% tween-20 before
incubating for one hour with goat anti-mouse horse-radish-peroxidase-conjigated
(Santa Cruz) at a 1:2,500 dilution in TBS with 0.05 tween-20. All incubations
were performed at room temperature. Proteins were detected using Pierce
Supersignal substrate (Thermoscientific Pierce, Waltham, MA) in a Fuji LAS3000 Bioimager (Tokyo, Japan) at 30 second intervals.
Enzyme-linked immunosorbent assay (ELISA)
Concentrations of IgA and γ2b in cell lysates were analyzed as described
previously (Henseler, et al. 2009). Colorimetric detection was performed every
minute for 1 hour using a Spectramax Plus 284 automated microplate reader with
a 405-nm filter (Molecular Devices, Sunnyvale, CA). Sample concentrations of
IgA and γ2b were calculated by the SOFTmax PRO analysis software (Molecular
Devices) using a standard curve generated from the kinetic rate of absorption for
known IgA or γ2b concentrations.
RNA Isolation
After the incubation period, cells were centrifuged at 3000 rpm, collected in 0.25
mL of TRI Reagent (Sigma-Aldrich, St. Louis, MO), and stored at -80˚C.
Samples were thawed at room temperature and centrifuged at 12,000 x g for 10
minutes. The supernatant was collected into Phase Lock Gel Tubes (5 PRIME,
Gaithersburg, MD), mixed with 0.1 volume of 1-bromo-3-chloropropane followed
by a 10 minute room temperature incubation and the addition of 0.1 volume of
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nuclease-free water. Samples were then centrifuged at 12,000 x g for 5 minutes.
The aqueous phase was retained and mixed with 0.125 mL isopropanol then
centrifuged at 12,000 x g for 8 minutes to precipitate RNA. The RNA pellet was
washed with 0.25 mL 70% ethanol, air dried, and suspended in nuclease-free
water. Samples were stored at -20˚C until analysis.
cDNA Synthesis and Real-Time PCR
RNA concentrations of samples were quantified using a NanoDrop ND-1000
spectrophotometer (NanoDrop Products, Wilmington, DE). One microgram of
total RNA was converted to cDNA using the TaqMan Reverse Transcriptase Kit
(ABI, Carlsbad, CA) and the standard manufacturer’s protocol.

The cycling

conditions for reverse transcription were as follows, 25˚C for 10 min, 48˚C for 30
min, and 95˚C for 5 min. Cyp1A1 expression in wild type, CH223191-treated,
and shAhR cell lines was determined by SYBR Green Real-Time PCR (RT-PCR)
following TCDD treatment. Cyp1A1 and β-actin (endogenous control) transcripts
were amplified from 5 ng cDNA utilizing the following primers: Cyp1A1 forward
primer (FP), 5’ AAGTGCAGATGCGGTCTTCT 3’; Cyp1A1 reverse primer (RP),
5’ AAAGTAGGAGGCAGGCACAA 3’; β-actin FP, 5’GCTACAGCTTCACCACCACA-3’; β-actin RP, 5’TCTCCAGGGAGGAAGAGGAT-3’. cDNA was combined with 6 pmol of both FP
and RP, 2 X SYBR Green, and diluted to 25 µL with nuclease-free water.
Separate RT-PCR reactions were performed for Cyp1A1 and β-actin using an
ABI 7500 with cycling conditions of 50˚C for 2 min, 95˚C for 10 min, and 40
cycles of 95˚C for 15 sec and 60˚C for 1 min. Relative Quantification (RQ)
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values (i.e. fold-change) were determined by the ABI 7500 SDS 2.0. Because
Cyp1A1 has little to no expression in the absence of an AhR ligand (i.e. naïve
and vehicle-treated cells), Cyp1A1 expression is presented as a fold change
(RQ) from the highest Cyp1A1-activating TCDD concentration (10 nM) which was
set to one.
Statistical Analysis
The mean±SE (n=4) was calculated for all treatment groups of each ELISA
experiment. IgA and γ2b expression are shown as a percent of the DMSO
control. The DMSO control mean was set to 100% and the data was
transformed to a percent of the mean. The IgA or γ2b figures are representative
of 3-4 experiments. Significance of treatments from vehicle controls was
determined by a 1-way ANOVA and Dunnett post hoc test.

Significant

differences in Cyp1A1 transcript expression from 10 nM TCDD (qRT-PCR) in
Wild Type cells were determined by a one-tailed t test.

16

III.

RESULTS

Stable knockdown of the AhR and the AhR antagonist CH223191 disrupt
canonical AhR signaling in the CH12.LX B cell line
To determine if the AhR mediates TCDD-induced inhibition of Ig expression by
disrupting 3'IghRR transcriptional activity, we utilized an IgA-expressing CH12.LX
cell line variant that stably expresses a γ2b transgene regulated by the 3'IghRR
(CH12.γ2b-3'IghRR cells) (Henseler et al., 2009). CH12.γ2b-3'IghRR cells were
stably transduced with lentiviral particles containing shRNA targeted to the AhR.
Highly variable levels of AhR-knock down were observed by western blot during
the course of screening >100 cell populations from CH12.γ2b-3'IghRR cells
transduced with lentiviral particles containing five separate shRNA sequences
targeted to AhR (data not shown). Two independent shRNA sequences
(denoted shAhR11 and shAhR12) stably knocked down AhR by at least 50%
(Fig.1). In order to ensure results seen in the shAhR cell populations were not
the result of shRNA off target effects, we also utilized the previously
characterized competitive AhR antagonist, CH-223191, to disrupt AhR signaling
in the CH12.γ2b-3'IghRR cells (Kim et al., 2006; Zhoa et al., 2010). Cytochrome
P4501A1 (Cyp1A1) is robustly expressed as a direct result of ligand-activated
AhR binding to DREs within the Cyp1A1 gene promoter (Reviewed by Beischlag
et al., 2008). Concentration-response experiments were performed in order to
17

find the most effective concentration of CH-223191 for disrupting TCDD-AhR
signaling. TCDD-induced up regulation of Cyp1A1 has been used extensively to
assess functional AhR-signaling in various cell types including CH12.LX B cells
and primary human B cells. Both stable AhR knockdown and CH-223191
treatment disrupted canonical AhR-signaling as evidenced by a dramatic
inhibition of TCDD-induced Cyp1A1 transcript expression validating our
experimental models (Fig. 6).
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Figure 6. Effect of reduced AhR expression and a competitive AhR
antagonist (CH-223191) on TCDD-induced CYP1A1 expression. “Wild Type”
(WT) refers to CH12.LX murine B-cells that endogenously express IgA and stably
express a 3’IghRR-regulated γ2b transgene (CH12.γ2b-3’IghRR cells). “shAhR”
denotes CH12.γ2b-3’IghRR cells that stably express shRNA to AhR (shAhR).
Stable expression of shAhR was achieved using lentiviral-mediated delivery of
shAhR constructs (denoted shAhR11 and shAhR12). (A); Whole cell lysates
were collected from WT and shAhR cells. 20 µg of protein was subjected to
western blot analysis of AhR and β-actin proteins. (B); WT, shAhR11, and
shAhR12 cells (5.0 x 105 cells/mL) were culture in the presence of 10 nM TCDD,
0.11% DMSO vehicle, or left in the absence of treatment (NA) for 8 hours. WT
cells were also subjected to 30 µM AhR Antagonist (CH-223191) treatment
(AhRA) for 1 hour prior to TCDD. Total RNA was extracted, one microgram was
reverse transcribed to cDNA, and 5 ng of cDNA was used to amplify Cyp1A1 and
β-actin via SYBR Green real-time PCR. NA and DMSO treatment caused no
appreciable expression of Cyp1A1 as it is only expressed when activated my
ligand (i.e. TCDD), therefore results are expressed as relative quantification (RQ)
values compared to TCDD-treated WT cells. The data is representative of at
least two separate experiments (n=3 for each treatment group). Statistical
differences compared to respective WT TCDD treatment group were determined
by a one-tailed t test.
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Disrupting AhR signaling reverses TCDD-induced inhibition of 3’IghRR
activation and Ig expression in LPS-activated B cells
AhR has long been suspected to mediate TCDD-induced inhibition of Ig
expression, as supported by structure-activity relationships revealing that ligands
with increasing affinity for the AhR inhibit the Ig expression with greater
sensitivity (Sulentic et al., 2000). In addition, AhR null mice and an AhR-deficient
murine B cell line (BCL-1) are refractory to TCDD treatment further highlighting
the importance of the AhR in mediating the inhibitory effect of TCDD on Ig
expression (Vorderstrasse et al., 2001; Sulentic et al., 1998). However despite
extensive study, there remains a paucity of mechanistic data to explain how the
AhR regulates Ig expression. Our lab has previously shown that a key regulator
of Igh transcription and therefore Ig production, the 3'IghRR, not only contains
putative DRE sites but is also sensitive to a variety of AhR agonists (Fernando et
al., 2012; Henseler et al., 2009). Despite a putative link, the role of the AhR in
directly mediating these effects was not established.
At this time no cis-acting transcriptional target has been identified that
links ligand-activation of the AhR to inhibition of Ig expression. Due to its
sensitivity to AhR-ligands, the presence of DREs, and its paramount importance
to Ig expression and CSTR, the 3'IghRR is a likely transcriptional target of the
AhR. As such we sought to elucidate the correlative link between the AhR and
the 3'IghRR using a competitive AhR antagonist (CH-223191) or shRNA targeted
to AhR in CH12.γ2b-3'IghRR cells (denoted shAhR11 and shAhR12) allowing for
simultaneous surveillance of AhR-dependent changes in 3'IghRR transcriptional
activity and Ig expression. Consistent with our previous studies, TCDD inhibited
20

LPS-activation of both the γ2b transgene and endogenous IgA proteins (Fig. 7
and 8). Following a one hour pretreatment with CH-223191 (30 µM), TCDDinduced inhibition of both the γ2b transgene and endogenous IgA protein was
completely mitigated (Fig. 7). In addition both shAhR11 and shAhR12 cell
models were refractory to TCDD-treatment compared to the wild type (CH12.γ2b3'IghRR) parental cells (Fig. 8). Our data support a direct effect on the 3'IghRR
that is mediated either by binding of the AhR to DREs in the 3'IghRR enhancers
and/or interaction of the AhR with other transcription factors regulating 3'IghRR
activity, which results in 3'IghRR inhibition and thus IgA expression.
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Figure 7. TCDD-induced inhibition of a 3'IghRR-regulated γ2b transgene
and endogenous IgA protein expression is reversed by an AhR Antagonist
(CH-223191). CH12.γ2b-3'IghRR cells were pretreated for 1 h with CH-223191
(30 µM) or vehicle (0.1% DMSO) followed by treatment for 48 h with TCDD (10
nM) or vehicle (0.01% DMSO) in the presence of LPS stimulation (1 µg/mL). (A);
γ2b and IgA expression (mean±S.E., n=4) normalized to 2 µg total protein was
determined by ELISA. (B); γ2b and IgA expression transformed to percent effect
with the DMSO control set to 100%. NA denotes the naïve control. Significance
was determined by a 1-way ANOVA followed by a Dunnet post hoc test. “**” and
“*” denote significance from the DMSO control at p<0.01 and p<0.05
respectively. “‡‡‡” and “‡‡” denote significance of the NA control from the LPS
control at p<0.001 and p<0.01 respectively.
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Figure 8. Down-regulation of AhR by shRNA reverses TCDD-induced
inhibition of the 3'IghRR-regulated γ2b transgene and endogenous IgA
protein expression. CH12.γ2b-3'IghRR (Wild Type) cells stably transduced with
lentivirus containing one of two shRNA-containing transgenes targeted to AhR
(denoted by shAhR11 and shAhR12). Wild Type and shAhR cells were treated
with vehicle (0.1% DMSO) and TCDD (10 nM) in the presence of LPS (1 µg/mL)
stimulation for 48 hours. Data represents γ2b (A) and IgA (B) expression as
determined by ELISA in 2 µg total protein and transformed to percent effect
(mean±S.E., n=4) with the DMSO control set to 100%. NA denotes the naïve
control. Significance was determined by a 1-way ANOVA followed by a Dunnet
post hoc test. “**” and “*” denote significance from the DMSO control at p<0.01
and p<0.05 respectively. “‡‡‡” and “‡‡” denote significance of the NA control
from the LPS control at p<0.001 and p<0.01 respectively.
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IV.

DISCUSSION

Compromised immune function, specifically suppressed Ig expression, is
one of the most sensitive toxicological consequences in TCDD-treated laboratory
animals (Reviewed by Sulentic and Kaminski, 2012). Although established to be
AhR-dependent, a mechanism has remained elusive and is a significant human
health question given the plethora of nondioxin compounds of pharmaceutical
and dietary origin shown to modulate the AhR (Reviewed by Stejskalova et al.,
2011). Indeed, a recent study by Lu et al. (2010) revealed the CD40 liganddependent Ig response of human peripheral B cells is inhibited by TCDD
highlighting the need to thoroughly identify the mechanism of AhR-dependent
inhibition of Ig expression to determine risk to human health. In the current study
we show that both pharmacological inhibition of the AhR and knock down of AhR
protein levels fully reverses concomitant inhibition of the 3'IghRR, a critical Ig
gene regulator, and Ig expression in TCDD-treated CH12.LX mouse B cells. For
the first time a transcriptional target for the AhR (the 3'IghRR) critical for Ig
expression has been identified addressing a crucial mechanistic data gap in the
literature. We propose a mechanism in which the AhR inhibits the capacity of the
3'IghRR to increase Igh transcription leading to decreased Ig expression.
The mouse 3’IghRR (mo-3’IghRR) is a large ~40 kb region and contains at
least four enhancer domains (i.e. hs3A, hs1,2; hs3B; hs4) with binding sites for
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many transcription factors including a DRE capable of binding the AhR within
both the hs1,2 and hs4 enhancers (Reviewed by Pinaud et al., 2011; Sulentic et
al., 2000). A single enhancer or a combination of these enhancers or specific
transcription factor binding sites within the enhancers along with the AhR may
direct the overall inhibition of the mo-3'IghRR. Relevant to this notion is the
strikingly different transcriptional behavior exhibited by the hs1,2 and hs4
enhancers when in isolation in luciferase reporter constructs. While
transcriptional activity of the hs1,2 enhancer is inhibited by TCDD, the hs4
enhancer is syngeristically activated by TCDD and LPS treatment in CH12.LX B
cells (Fernando et al., 2012; Sulentic et al., 2004).
Undoubtedly luciferase reporter constructs evaluating individual
enhancers may not mimic enhancer behavior in the context of the entire mo3'IghRR and chromatin. We previously reported that expression of a stablyexpressed γ2b reporter construct under transcriptional control of either the entire
mo-3'IghRR or the hs1,2/hs3A enhancer pair is inhibited by TCDD (Henseler et
al., 2009; Fernando et al., 2012). In our current study we show that an AhR
antagonist ameliorates TCDD- dependent inhibition of not only the mo-3'IghRR
but also the hs1,2/hs3A enhancer pair further suggesting that the DREcontaining, hs1,2 is the primary target of TCDD-AhR. Indeed, TCDD was
recently shown to modulate the human hs1,2 (hu-hs1,2) enhancer in a
concentration-dependent manner (Fernando et al., 2012). Clearly predicting the
behavior (i.e. inhibition vs. activation) of AhR-sensitive genes cannot be
restricted to the simple identification of a DRE (e.g. hs1,2 and hs4 enhancers)
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and must be considered in the context of the entire transcriptional unit in which a
DRE is located. At least in the case of mouse B cells, TCDD inhibits Ig
expression in an AhR-dependent manner by modulating the mo-3'IghRR, and
perhaps specifically the seemingly dominant hs1,2 enhancer.
The structure of the human 3'IghRR (hu-3'IghRR) and the behavior of its
constituent enhancers diverges slightly from that of the mo-3'IghRR perhaps
complicating the translation of mo-3'IghRR studies to hu-3'IghRR and
understanding the role of the 3'IghRR in possible AhR-dependent inhibition of Ig
expression in human B cells. The 3'IghRR is duplicated in the human Igh locus
and consists of only the hs3A, hs1,2 and hs4 enhancers (Chen and Birshstein,
1997).
Interestingly the hu-hs1,2 is highly polymorphic, characterized by an ~38
bp invariant sequence (IS) that contains a DRE-like site and may be repeated in
tandem up to three times (Denizot et al., 2001; Fernando et al., 2012). Studies
using the AhR Antagonist CH-223191 revealed that hu-hs1,2 enhancers
containing one, two, or three copies of the IS are activated by TCDD in an AhRdependent manner, albeit to varying extents depending upon the number of IS
(Fernando et al., 2012). However, the aforementioned study was performed
using a transiently expressed reporter-plasmid system and may not be reflective
of the full hu-3'IghRR. Indeed, despite TCDD-dependent activation of the mohs4 enhancer in luciferase-reporter constructs, transcriptional activity of the
stably expressing γ2b-3'IghRR reporter construct inhibited. Furthermore, a
recent study showed nine of twelve human donor primary B cells to have
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reduced Ig expression when treated with TCDD (Lu et al., 2010). The study also
reported two nonresponsive donors while one donor exhibited enhanced Ig
expression with TCDD treatment. Enhanced Ig production (IgE) by TCDD has
been reported in tonsillary B lymphocytes but only from atopic patients who are
predisposed to type I hypersensitivity reactions, a hallmark of which is aberrant
IgE production (Kimata, 2003). It is possible that an underlying genetic condition
in the regulatory machinery of Ig, such as a polymorphism in the 3'IghRR and/or
the hs1,2 enhancer, may cause deleterious enhancement of Ig expression when
activated by an AhR ligand. The combination of several single nucleotide
polymorphisms (SNP) in human AhR is known to cause deficient TCDD-induced
Cyp1A1 induction and may have explained the nonresponsive donors, but these
SNPs were not detected in the author’s study (Reviewed by Harper et al., 2001;
Lu et al., 2010). It is tempting to surmise that heterogeneity of the human Ig
response to TCDD (or other AhR-activators) is due to heterogeneity of the huhs1,2 or other elements within the 3’IghRR and/or the heterogeneity of AhR
polymorphisms, however many factors, discovered and undiscovered likely play
a role.
Deficient Ig expression in response to TCDD has been well established for
over thirty years in mouse models however the literature contains a paucity of
mechanistic data (Reviewed by Sulentic and Kaminski, 2010). To the best of our
knowledge no study has identified a cis-acting transcriptional target for the AhR
that explains AhR-dependent inhibition of Ig expression; therefore our study fills a
critical mechanistic data gap. Recent evidence suggests that a proportion of the
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human population is also be sensitive to the inhibitory effect of TCDD, a finding
that may be due in part to AhR-dependent modulation of the hu-hs1,2 enhancer
within the human 3'IghRR (Lu et al., 2010; Fernando et al., 2012). Interestingly
IS within the hu-hs1,2 have been correlated with the incidence of many immunerelated diseases including celiac disease, IgA nephropathy, systemic sclerosis,
plaque psoriasis, psoriatic arthritis, dermatitis herpetiformis, and rheumatoid
arthritis (Frezza et al., 2004; Aupetit et al., 2000; Frezza et al., 2007; Cianci et al.,
2008; Tolusso et al., 2009).
Given the growing number of dietary and pharmaceutical AhR-ligands and
persistent presence of dioxin-related compounds in the environment, modulation
of the hu-1,2 may have the capacity to alter the incidence and/or the severity of
human diseases in addition to interfering with the Ig response (Reviewed by
Stejskalova et al., 2011). Understanding the role of the AhR-dependent
modulation of the human 3'IghRR would provide valuable insight into the
identification and quantification of human health risks. Furthermore, interactions
of the hu-h1,2 and the AhR and/or other transcription factors that bind within the
hu-hs1,2 and the 3'IghRR may provide opportunities for therapeutic intervention
in many immune-related disorders.
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